Novus Therapeutics is a pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat. Co. has two platform technologies, a surfactant and a foam. Co.'s primary program, OP0201, is a surfactant-based nasal aerosol drug-device combination product candidate being developed as a treatment option for patients at risk for, or with, otitis media (OM). OM is defined as middle ear inflammation and effusion with or without infection. Co. also has a foam-based drug delivery technology platform, which may be developed to deliver drugs into the ear, nasal, and sinus cavities. The NVUS average annual return since 2014 is shown above.
The Average Annual Return on the NVUS average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NVUS average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NVUS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
